Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 48.00 6 08:14:59
Bid Price Offer Price High Price Low Price Open Price
45.00 50.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 125.06 -9.18 -1.93 338
Last Trade Time Trade Type Trade Size Trade Price Currency
10:03:11 O 6 49.50 GBX

Benchmark (BMK) Latest News (1)

More Benchmark News
Benchmark Investors    Benchmark Takeover Rumours

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
09/6/202215:44Benchmark Holdings Plc458
19/5/202108:35SALMON prices 30 year high and CAT VACCINES are Go-Go566

Add a New Thread

Benchmark (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-29 15:20:3750.001,211605.50AT
2022-06-29 15:06:2648.007,5003,600.00AT
2022-06-29 15:06:2648.00500240.00AT
2022-06-29 15:06:2448.007,0003,360.00AT
View all Benchmark trades in real-time

Benchmark (BMK) Top Chat Posts

Benchmark Daily Update: Benchmark Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 48p.
Benchmark Holdings Plc has a 4 week average price of 48p and a 12 week average price of 39p.
The 1 year high share price is 65p while the 1 year low share price is currently 39p.
There are currently 703,779,104 shares in issue and the average daily traded volume is 1,952,559 shares. The market capitalisation of Benchmark Holdings Plc is £337,813,969.92.
edmonda: New research report (free access): "Financial update highlights strong outlook" Benchmark reported a fourth sequential quarter of revenue and AEBITDA profit growth in the January-March (Q2) period, highlighting the continued favourable trends in its three business areas. The group has, so far, been largely unaffected by the post February economic shock and maintains that it continues to have a strong outlook in its important salmon egg and nutrition businesses for the remainder of the year. Key points to note include: Q2 results: revenues were up by 29% at £39.3m, reflecting strong growth in the three divisions of Nutrition (+16%), Genetics (+20%) and Health (+390%). These were broadly consistent with or ahead of our expectations. Safe haven status: Benchmark’s alignment to the aquaculture segment should mean it is largely insulated from economic disruption caused by the Russian invasion of Ukraine and associated sanctions. Balance sheet: Benchmark has a strong balance sheet with cash of £46.2m and net debt of £81.4m on 31st March, which is a positive element in the investment case. We expect the company will look to refinance its NOK855m bond in the second half of 2022. We have also revised our DCF-valuation to reflect forecasts and now assume a higher cost of capital more appropriate to the current inflation/interest rate environment. Our model yields a fair valuation of £478m or 68p/share, versus the current 51p level. Link to full research report:
hedgehog 100: It's interesting to note BMK's strong cash position: "Cash of £50.6m and Liquidity (cash and available facility) of £61.6m as at 21 February 2022" Considering the buy-&-build strategy employed by BMK, then OTAQ, which has BMK founder Malcolm Pye as a director, could be a potential BMK takeover target. In fact, at its current share price of just 20.5p OTAQ looks a sitting duck for a BMK takeover attempt, and looks a prefect fit. Thought I think that it would have to pay at least double or treble OTAQ's current share price to succeed. "Malcolm Pye Non Executive Director Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement." HTTP://
edmonda: #BMK Benchmark’s recent Q1 FY22 results highlighted strong operating trends in its three business areas and a positive outlook in key end-markets, especially farmed salmon. The group’s strong position serving the aquaculture industry should, in our view, insulate it from economic shocks resulting from the geo-political situation and thus make for attractive, safe haven investment. The company has a strong balance sheet and liquidity position following its £20m equity fundraising last year, which we consider will become a more prominent positive element in its investment case. However, Benchmark will have to refinance its NOK855m senior bond, which falls due on in July 2023. Doing so would remove something that may otherwise become an overhang as it approaches the due date. Benchmark will have to contend with significant input cost inflation and will undoubtedly see some knock-on effects from disruption to its customers’ end markets. Although the Q1 results would ordinarily have supported a modest upgrade, we have decided to maintain our current financial forecasts pending greater clarity. These forecasts support a DCF-based valuation of £583m, equivalent to 83p/share.
murdo mcsponge: ...and the Market Price falls. Strange creatures some investors.
km18: ...from a while ago ... Benchmark Holdings issued a trading update earlier in the week. There is continued good momentum across all business areas, FY21 results are expected to be significantly ahead of market expectations. The Group's Adjusted EBITDA for FY21 is expected to be significantly ahead of the current market consensus which is £15.9m. This suggests that the company could even post positive EPS in FY21 for the first time in 7 years. But valuation is not particularly attractive, PS ratio of near 4 is bottom half for the Pharmaceuticals sector. The company ran at a loss for 7 years in a row between FY14 and FY20, there is no rush to buy here. But BMK is quite an interesting company and perhaps a share to monitor for now....from WealthOracleAM
edmonda: #BMK - save the date! Benchmark Holdings plc, the aquaculture biotechnology company, will be conducting an investor webinar following publication of their Q1 results. The online presentation will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO. This event will take place at 12.00pm on Tuesday 22nd February. Sign up here at the link:
edmonda: #BMK Benchmark Holdings’ FY21 and particularly its Q4 (July to September) results confirmed the strong recovery in the business, led by its nutrition business, that had been indicated in the October pre-close trading update. An improving outlook in its key shrimp market and good conditions in the salmon and sea bass/bream sectors underpins an upgrade of our financial forecasts for FY22 and beyond. With £20m raised via a placing, Benchmark is now in a stronger position to invest in capital expansion projects ahead of the refinancing of its NOK bond, which falls due in 2023. A possible share listing in Norway next year may also provide better access to aquaculture-specific investors/capital. Taken together, these elements boost our overall valuation. We have updated our model and increased our expectations across the board to reflect the current outlook and trends as well as the placing of 33m shares at 62p/share. Our revised estimate of the fair value is now £583m, up from £550m, which is equivalent to 83p/share based on the enlarged share count.
tomps2: Benchmark (BMK) full year 2021 results presentation - November 2021 Benchmark’s CEO, Trond Williksen and CFO, Septima Maguire present the full year results for the period ended 30th September 2021. Watch the video here: Https:// Or listen to the podcast here: Https://
cordwainer: What a lack-lustre share it seems over the past 7 years, although I've only been following / holding since July. I get the feeling it's permanently overlooked because maybe it's a somewhat unglamorous non-trendy industry. ^ btw, i like using "imho" sometimes because i know i'm not God's gift to company share analysis.
murdo mcsponge: That's been my belief. If they have come up with either disease resistant shrimp, or a way of stimulating something akin to an immune response, I believe that would be a serious winner with a very big market. I thought that Shrimp didn't have an immune response, and I did ask Malcolm Pye about it at an AGM about 3 or 4 years ago, and he indicated that while they don't have the sort of immune system that we recognize, they do have some sort of system for fighting off infections. If BMK have something, the market should be enormous, and it's one of the main reasons BMK is the biggest holding in my Portfolio.
Benchmark share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220630 09:50:27